References
1. Park YB, Rhee CK, Yoon HK, Oh YM, Lim SY, Lee JH, et al. 2018;COPD clinical practice guideline of the Korean Academy of Tuberculosis and Respiratory Disease: a summary. Tuberc Respir Dis (Seoul) 81:261–73.
2. Barnes PJ, Shapiro SD, Pauwels RA. 2003;Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 22(4):672–88.
3. Kim IA, Park YB, Yoo KH. 2004;Pharmacotherapy for chronic obstructive pulmonary disease. J Korean Med Assoc Sep. 61(9):545–551.
4. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, et al. 1994;Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. JAMA 272:1497–505.
5. Singh S, Amin AV, Loke YK. 2009;Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 169:219–29.
6. Barnes PJ. 2013;New anti-inflammatory targets for chronic obstructive pulmonary disease. Nat Rev Drug Discov 12(7):543–59.
7. Lee ES, Han JM, Kim MH, Namgung U, Yeo Y, Park YC. 2013;Effects of inhalable microparticles of Socheongryong-tang on chronic obstructive pulmonary disease in a mouse model. J Korean Med 34(3):54–68.
8. Lee JG, Yang SY, Kim MH, Namgung U, Park YC. 2011;Protective effects of Socheongryong-tang on elastase-induced lung injury. J Korean Oriental Med 32(4):83–99.
9. Kim Y, Yang SY, Kim MH, Namgung U, Park YC. 2011;Effects of Saengmaekcheongpye-eum on LPS-induced COPD model. Korean J Oriental Int Med 2011;32(2):217–31.
10. Kim HW, Yang SY, Kim MH, Namgung U, Park YC. 2011;Protective effects of Maekmundong-tang on elastase-induced lung injury. J Korean Oriental Med 32(2):63–78.
11. Lee H, Kim Y, Kim HJ, Park S, Jang YP, Jung S, et al. 2012;Herbal Formula, PM014, Attenuates Lung Inflammation in a Murine Model of Chronic Obstructive Pulmonary Disease. Evid Based Complement Alternat Med 2012;:769830.
12. Han JM, Yang WK, Kim SH, Park YC. 2015;Effects of Sagan-tang and individual herbs on COPD mice model. J Korean Med Soc Herb Formula Study 23(2):171–87.
13. Park JJ, Yang WK, Lyu YR, Kim SH, Park YC. 2019;Inhibitory effects of SGX01 on lung injury of COPD mice model. Korean J Int Korean Med 40(4):567–81.
14. Yang WK, Lyu YR, Kim SH, Park YC. 2018;Effects of GHX02 on Chronic Obstructive Pulmonary Disease Mouse Model. J Korean Med 39(4):126–35.
15. Kim SH, Hong JH, Yang WK, Geum , et al. 2020;Herbal combinational medication of Glycyrrhiza glabra, Agastache rugosa containing Glycyrrhizic acid, Tilianin inhibits Neutrophilic lung inflammation by affecting CXCL2, Interleukin-17/STAT3 signal pathways in a murine model of COPD. Nutrients 12(4):926.
16. Yang L, Li J, Li Y, Tian Y, Li S, Jiang , et al. 2015;Identification of metabolites and metabolic pathways related to treatment with Bufei Yishen formula in a rat COPD model using HPLC Q-TOF/MS. Evidence-Based Complementary and Alternative Medicine, 2015
17. Hwang DY. 1986. Bang-yak-hap-pyeon Seoul: Namsandang. p. 240.
18. Lyu YR. 2020. Inhibitory effects of GGX in a particulate matter-induced lung injury mouse model. doctoral dissertation Daejeon university;
19. Hong HW. 2011. The Effects of Kamgiltang on Passive Smoking in Rats. doctoral dissertation Dong-eui University.
20. Mizutani N, Fuchikami J, Takahashi M, Nabe T, Yoshino S, Kohno S. 2009;Pulmonary emphysema induced by cigarette smoke solution and lipopolysaccharide in guinea pigs. Biol Pharm Bull 32(9):1559–64.
21. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, et al. 2006;Chronic obstructive pulmonary disease: current burden and future projections. Eur Rspir J 27(2):397–412.
22. Mathers CD, Loncar D. 2006;Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3(11):e442.
23. An TJ, Yoon HK. 2018;Prevalence and socioeconomic burden of chronic obstructive pulmonary disease. J Korean Med Assoc 61(9):533–8.
24. GBD 2015 Chronic Respiratory Disease Collaborators. 2017;Global, regional, and national deaths, prevalence, disability adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015 a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med 5(9):691–706.
25. Jung YM, Lee H. 2011;Chronic obstructive pulmonary disease in Korea: Prevalence, risk factors, and quality of life. J Korean Acad Nurs 41(2):149–56.
26. Ministry of Gender Equality & Family (MOGEF). 2014. 2014 Comprehensive survey on the contact with the harmful environment for youth Available at: URL:
http://www.mogef.go.kr
. Accessed April 1.
27. Yoon J, Seo H, Oh IH, Yoon SJ. 2016;The Non-Communicable Disease Burden in Korea: Findings from the 2012 Korean Burden of Disease Study. J Korean Med Sci Nov. 31(Suppl 2):S158–S167.
28. Park SK. 2002;Chronic obstructive pulmonary disease - definition, severity, risk factors, etiology, pathology, diagnosis. J Korean Med 63(2):389–99.
29. Lurwidya F, Damayanti T, Yunus F. 2016;The Role of Innate and Adaptive Immune Cells in the Immunopathogenesis of Chronic Obstructive Pulmonary Disease. Tuberc Respir Dis(Seoul) 79(1):5–13.
30. Lee S, et al. 2007;Antielastin autoimmunity in tobacco smokinginduced emphysema. Nature Med 13:567–569.
31. Yoo CG. 2009;Pathogenesis and pathophysiology of COPD. Korean J Med 77(4):383–400.
32. Barnes PJ. 2004;Macrophages as orchestrators of COPD. COPD 1:59–70.
33. Majo J, Ghezzo H, Cosio MG. 2001;Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur Respir J 17:946–53.
34. Barnes PJ. 2008;The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest 118(11):3546–56.
35. Rovina N, Koutsoukou A, Koulouris NG. 2013;Inflammation and immune response in COPD: where do we stand? Mediators Inflammation 2013;:413735.
36. Herbology Editorial Committee of Korean Medicine schools. 1991. Boncho-hak Seoul: Younglimsa. p. 124–5.
p. 136–7.
p. 214–5.
p. 448–9.
p. 534–5.
p. 580–1.
p. 588–9.
37. Park YC, Jin M, Kim SH, Kim MH, et al. 2014;Effects of inhalable microparticle of flower of Lonicera japonica in a mouse model of COPD. Journal of Ethnopharmacology 151(1):123–130.
38. Di Stefano A, Capelli A, Lusuardi M, Balbo P, Vecchio C, Maestrelli P, et al. 1998;Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med 158(4):1277–85.
39. Aaron SD, Angel JB, Lunau M, Wright K, Fex C, Le Saux N, et al. 2001;Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 163(2):349–55.
40. Deveci Y, Deveci F, Ilhan N, Karaca I, Turgut T, Muz MH. 2010;Serum ghrelin, IL-6 and TNF-α levels in patients with chronic obstructive pulmonary disease. Tuberk Toraks 58(2):162–72.
41. Traves SL, Donnelly LE. 2008;Th17 cells in airway diseases. Curr Mol Med 8(5):416–26.
42. Levänen B, Glader P, Dahlén B, Billing B, Qvarfordt I, Palmberg L, et al. 2016;Impact of tobacco smoking on cytokine signaling via interleukin-17A in the peripheral airways. Int J Chron Obstruct Pulmon Dis 11:2109–16.
43. Lukacs NW, Hogaboam CM, Kunkel SL. 2005;Chemokines and their receptors in chronic pulmonary disease. Curr Drug Targets Inflamm Allergy 4(3):313–7.
44. Traves SL, Culpitt SV, Russell RE, Barnes PJ, Donnelly LE. 2002;Increased levels of the chemokines GROα and MCP-1 in sputum samples from patients with COPD. Thorax 57(7):590–5.
45. Culpitt SV, Rogers DF, Shah P, De Matos C, Russell RE, Donnelly LE, et al. 2003;Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 167(1):24–31.